71 results on '"Miele, Luca"'
Search Results
2. Non‐alcoholic fatty liver disease and the risk of fibrosis in Italian primary care services: GPS‐NAFLD Study.
- Author
-
Miele, Luca, Grattagliano, Ignazio, Lapi, Francesco, Dajko, Marianxhela, De Magistris, Antonio, Liguori, Antonio, De Matthaeis, Nicoletta, Rossi, Alessandro, Gasbarrini, Antonio, Cricelli, Claudio, and Grieco, Antonio
- Subjects
- *
NON-alcoholic fatty liver disease , *HEPATIC fibrosis , *PRIMARY care , *FATTY liver , *FIBROSIS - Abstract
Background and aims: The prevalence of non‐alcoholic fatty liver disease (NAFLD) is increasing globally. This study aimed to determine the prevalence of NAFLD and the probability of liver fibrosis in Italian primary care services. Methods: We carried out a population‐based and nested case–control study including all individuals aged 18 years and above registered at Italian primary care services. Data were collected from the general practitioners' network from 2010 to 2017. NAFLD cases were identified via the ICD‐9‐CM and Hepatic Steatosis Index score > 36 and were matched each up to 10 controls. Other causes of liver diseases were excluded. The risk of fibrosis was assessed using the FIB‐4 and NAFLD fibrosis scores (NFS). Results: NAFLD was present in 9% of the primary care population with high regional variability. Among NAFLD subjects: 25% had diabetes, 10% had chronic kidney disease, 11% had cardiovascular disease and 28% were obese. Furthermore, 30% had at least two comorbidities and 13% had cirrhosis. Once cirrhosis was excluded, the risk of any degree of fibrosis was 13.8% with NFS and 20.5% with FIB‐4 in subjects <65 years. Conclusions: Even if there is an identification gap in primary care, recorded cases with NAFLD have a high frequency of associated comorbidities. Despite regional variability, a close relation between cirrhosis and NAFLD exists (OR: 3.48, 95% CI: 3.23–3.76). Therefore, the use of non‐invasive tests should be promoted in primary care as a useful tool for the early identification of fibrosis risk, independently of evidence of steatosis. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
3. COVID‐19, adaptative immune response and metabolic‐associated liver disease.
- Author
-
Miele, Luca, Napodano, Cecilia, Cesario, Alfredo, De Magistris, Antonio, Pocino, Krizia, Basile, Umberto, Rapaccini, Gian L., Gasbarrini, Antonio, and Grieco, Antonio
- Subjects
- *
FATTY liver , *METABOLIC disorders , *COVID-19 , *LIVER diseases , *NON-alcoholic fatty liver disease , *IMMUNE response , *GUT microbiome - Abstract
Metabolic diseases are associated with a higher risk of a severer coronavirus disease 2019 (COVID‐19) course, since fatty liver is commonly associated with metabolic disorders, fatty liver itself is considered as a major contributor to low‐grade inflammation in obesity and diabetes. Recently a comprehensive term, metabolic (dysfunction) associated fatty liver disease (MAFLD), has been proposed. The hepatic inflammatory status observed in MAFLD patients is amplified in presence of severe acute respiratory syndrome coronavirus 2 infection. Intestinal dysbiosis is a powerful activator of inflammatory mediator production of liver macrophages. The intestinal microbiome plays a key role in MAFLD progression, which results in non‐alcoholic steatohepatitis and liver fibrosis. Therefore, patients with metabolic disorders and COVID‐19 can have a worse outcome of COVID‐19. This literature review attempts to disentangle the mechanistic link of MAFLD from COVID‐19 complexity and to improve knowledge on its pathophysiology. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
4. Diabetes and Insulin Therapy, but Not Metformin, Are Related to Hepatocellular Cancer Risk.
- Author
-
Miele, Luca, Bosetti, Cristina, Turati, Federica, Rapaccini, Gianlodovico, Gasbarrini, Antonio, La Vecchia, Carlo, Boccia, Stefania, and Grieco, Antonio
- Subjects
- *
TREATMENT of diabetes , *INSULIN therapy , *METFORMIN , *CANCER risk factors , *LIVER cancer , *HYPOGLYCEMIC agents - Abstract
Introduction. Metabolic conditions, including type 2 diabetes, have been related to hepatocellular carcinoma (HCC) risk. We have further analyzed the role of diabetes and antidiabetic treatments on HCC. Methods. Data derived from a hospital-based case-control study (Italy, 2005–2012) on 224 HCC patients and 389 controls. Odds ratios (ORs) were estimated using multiple logistic regression models. Results. Sixty-nine (30.9%) cases versus 52 (13.5%) controls reported a diabetes diagnosis, corresponding to a multivariate OR of 2.25 (95% confidence interval, CI = 1.42–3.56). A stronger excess risk emerged for a longer time since diabetes diagnosis (OR = 2.96 for <10 years and 5.33 for ≥10 years). Oral therapies were inversely, though not significantly, related to HCC risk, OR being 0.44 for metformin and 0.88 for sulfonylureas; conversely, insulin was nonsignificantly directly associated (OR = 1.90). Compared to nondiabetic subjects who were never smokers, those who were diabetics and ever smokers had an OR of 6.61 (95% CI 3.31–13.25). Conclusion. Our study confirms an over 2-fold excess HCC risk in diabetics, with a stronger excess risk in diabetic subjects who are also tobacco smokers. Metformin may decrease the risk of HCC, whereas insulin may increase the risk. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
5. The Effect of CYP, GST, and SULT Polymorphisms and Their Interaction with Smoking on the Risk of Hepatocellular Carcinoma.
- Author
-
Boccia, Stefania, Miele, Luca, Panic, Nikola, Turati, Federica, Arzani, Dario, Cefalo, Consuelo, Amore, Rosarita, Bulajic, Milutin, Pompili, Maurizio, Rapaccini, Gianlodovico, Gasbarrini, Antonio, La Vecchia, Carlo, and Grieco, Antonio
- Subjects
- *
ACADEMIC medical centers , *CONFIDENCE intervals , *DEMOGRAPHY , *GENETIC polymorphisms , *MEDICAL protocols , *HEPATOCELLULAR carcinoma , *NUCLEOTIDES , *POLYMERASE chain reaction , *QUALITY of life , *RESEARCH funding , *SMOKING , *DATA analysis , *CONTROL groups , *ODDS ratio , *DIAGNOSIS , *DISEASE risk factors - Abstract
Aim. The aim of our study was to assess whether selected single nucleotide polymorphisms of CYP1A1 and 2E1, GSTM1, GSTT1, and SULT1A1 influence susceptibility towards HCC, considering their interaction with cigarette smoking. Methods. We recruited HCC cases and controls among patients admitted to the hospital “Agostino Gemelli,” from January 2005 until July 2010. Odds ratios (OR) of HCC were derived from unconditional multiple logistic regression. Gene-gene and gene-smoking interaction were quantified by computing the attributable proportion (AP) due to biological interaction. Results. The presence of any CYP2E1*5B variant allele (OR: 0.23; 95% CI: 0.06-0.71) and CYP2E1*6 variant allele (OR: 0.08; 95% CI: 0.01–0.33) was inversely related to HCC. There was a borderline increased risk among carriers of combined CYP1A1*2A and SULT1A1 variant alleles (OR: 1.67; 95% CI: 0.97–3.24). A significant biological interaction was observed between GSTT1 and smoking (AP = 0.48; 95% CI: 0.001–0.815), with an OR of 3.13 (95% CI: 1.69–5.82), and borderline significant interaction was observed for SULT1A1 and smoking (AP = 0.36; 95% CI: −0.021–0.747), with an OR of 3.05 (95% CI: 1.73–5.40). Conclusion. CYP2E1*5B and CYP2E1*6 polymorphisms have a favourable effect on the development of HCC, while polymorphisms of GSTT1 and SULT1A1 might play role in increasing the susceptibility among smokers. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
6. Glucokinase Regulatory Protein Gene Polymorphism Affects Liver Fibrosis in Non-Alcoholic Fatty Liver Disease.
- Author
-
Petta, Salvatore, Miele, Luca, Bugianesi, Elisabetta, Cammà, Calogero, Rosso, Chiara, Boccia, Stefania, Cabibi, Daniela, Di Marco, Vito, Grimaudo, Stefania, Grieco, Antonio, Pipitone, Rosaria Maria, Marchesini, Giulio, and Craxì, Antonio
- Subjects
- *
FATTY liver , *REGULATION of glucokinase , *PROTEIN genetics , *GENETIC polymorphisms , *FIBROSIS , *INFLAMMATION , *SINGLE nucleotide polymorphisms , *BLOOD serum analysis , *PATIENTS - Abstract
Background and Aims: Variant in glucokinase regulatory protein (GCKR), associated with lipid and glucose traits, has been suggested to affect fatty liver infiltration. We aimed to assess whether GCKR rs780094 C→T SNP influences the expression of steatosis, lobular inflammation and fibrosis in NAFLD patients, after correction for PNPLA3 genotype. Methods: In 366 consecutive NAFLD patients (197 from Sicily, and 169 from center/northern Italy), we assessed anthropometric, biochemical and metabolic features; liver biopsy was scored according to Kleiner. PNPLA3 rs738409 C>G and GCKR rs780094 C>T single nucleotide polymorphisms were also assessed. Results: At multivariate logistic regression analysis in the entire NAFLD cohort, the presence of significant liver fibrosis (>F1) was independently linked to high HOMA (OR 1.12, 95% CI 1.01–1.23, p = 0.02), NAFLD activity score ≥5 (OR 4.09, 95% CI 2.45–6.81, p<0.001), and GCKR C>T SNP (OR 2.06, 95% CI 1.43–2.98, p<0.001). Similar results were observed considering separately the two different NAFLD cohorts. GCKR C>T SNP was also associated with higher serum triglycerides (ANOVA, p = 0.02) in the entire cohort. Conclusions: In patients with NAFLD, GCKR rs780094 C>T is associated with the severity of liver fibrosis and with higher serum triglyceride levels. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
7. Nonalcoholic fatty liver disease is associated with increased GHBP and reduced GH/IGF-I levels.
- Author
-
Fusco, Alessandra, Miele, Luca, D'Uonnolo, Annalisa, Forgione, Alessandra, Riccardi, Laura, Cefalo, Consuelo, Barini, Angela, Bianchi, Antonio, Giampietro, Antonella, Cimino, Vincenzo, Landolfi, Raffaele, Grieco, Antonio, and De Marinis, Laura
- Subjects
- *
FATTY liver , *CARRIER proteins , *TESTOSTERONE , *MULTIVARIATE analysis , *CROSS-sectional method - Abstract
Introduction Nonalcoholic fatty liver disease (NAFLD) has been described in adult GH deficiency syndrome. Furthermore, chronic liver disease can be associated with significant changes in levels of IGF-I, GH-binding protein (GHBP), IGF-binding proteins (IGFBPs) and acid-labile subunit (ALS). However, the effect of liver steatosis on the GHBP production has not been investigated yet. Aim of the study To explore whether GH secretion and/or levels of IGF-I, IGFBP-3, ALS and GHBP could be altered in obese patients in relation to the presence of liver steatosis. Materials and methods A total of 115 obese patients (BMI > 30) were enrolled in the protocol (65 patients with liver steatosis and 50 age- and BMI-matched controls). In all patients, the following parameters were studied: serum levels of glucose, insulin, the HOMA index, IGF-I, GHBP, IGFBP-3, ALS and GH after GHRH and arginine stimulation test. Results As expected, patients with NAFLD had blood glucose, insulin, HOMA-R significantly higher than controls, indicating a more severe insulin-resistance state in NAFLD. Furthermore, patients with NAFLD had higher levels of GHBP and IGFBP-3 and lower GH peak and IGF-I levels as compared to controls. No difference was found in ALS levels between the groups. In a multivariate analysis, GHBP was positively associated with hepatic steatosis while IGF-1 was negatively associated with hepatic steatosis. Conclusions This study demonstrates that in patients with NAFLD, the GHBP levels are increased, and that the GH/IGF-I axis is significantly altered probably leading to reduced IGF-I bioavailability at tissue level. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
8. Long-term metformin treatment is able to reduce the prevalence of metabolic syndrome and its hepatic involvement in young hyperinsulinaemic overweight patients with polycystic ovarian syndrome.
- Author
-
Gangale, Maria F., Miele, Luca, Lanzone, Antonio, Sagnella, Francesca, Martinez, Daniela, Tropea, Anna, Moro, Francesca, Morciano, Andrea, Ciardulli, Andrea, Palla, Carola, Pompili, Maurizio, Cefalo, Consuelo, Grieco, Antonio, and Apa, Rosanna
- Subjects
- *
METABOLIC syndrome treatment , *METFORMIN , *OVERWEIGHT children , *POLYCYSTIC ovary syndrome , *FATTY liver , *OLIGOMENORRHEA , *DISEASES , *PATIENTS - Abstract
Summary Objective The objective of this study is to determine the ability of metformin treatment in reducing the prevalence of metabolic syndrome (MS) and its hepatic involvement in young hyperinsulinaemic overweight patients with polycystic ovarian syndrome (PCOS). Design Clinical Trial. Patients We recruited 140 hyperinsulinaemic overweight women with PCOS in their reproductive age. Metformin treatment (500 mg × 3/die) was prescribed to each patient for twelve months. Measurements The primary outcome was to evaluate the prevalence of nonalcoholic fatty liver disease (NAFLD) and MS in hyperinsulinaemic overweight patients with PCOS. The secondary outcome was to evaluate, in the same patients, the effects of metformin therapy on endocrine, metabolic and hepatic parameters. Results At basal evaluation, NAFLD was diagnosed in 81 of 140 patients with PCOS (57·85%); MS was present only in the NAFLD group (32·09% vs 0%; P < 0·001). After twelve months, metformin is able to significantly reduce, in the same group, the prevalence of MS (28·9% vs 13·5%; P < 0·01). An improvement of hepatic parameters and a significant decrease in oligomenorrhea (85·7% vs 19%, P < 0·001) were also observed. Conclusions Treatment with metformin is indicated in all hyperinsulinaemic overweight patients with PCOS, especially in those with NAFLD. These data appear even more interesting considering their increased risk to develop metabolic and hepatic complications. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
9. Prevalence, characteristics and severity of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis
- Author
-
Miele, Luca, Vallone, Selenia, Cefalo, Consuelo, La Torre, Giuseppe, Di Stasi, Carmine, Vecchio, Fabio M., D’Agostino, Magda, Gabrieli, Maria L., Vero, Vittoria, Biolato, Marco, Pompili, Maurizio, Gasbarrini, Giovanni, Rapaccini, Gianludovico, Amerio, Pierluigi, De Simone, Clara, and Grieco, Antonio
- Subjects
- *
FATTY liver , *DISEASE prevalence , *PSORIASIS , *CHRONIC diseases , *EPIDEMIOLOGY , *LONGITUDINAL method , *COHORT analysis , *ITALIANS , *PATIENTS , *DISEASES - Abstract
Background / Aims: The association between NAFLD and psoriasis has never been explored in prospective epidemiological studies. The aim of this 2-phase study was to study the clinical features of NAFLD in patients with psoriasis. Methods: Phase 1: Investigation of prevalence and characteristics of NAFLD in an unselected cohort of 142 adult Italian outpatients with psoriasis vulgaris. Phase 2: Comparison of the psoriasis cohort subgroup with NAFLD and an age- and body mass index-matched retrospective cohort of 125 non-psoriasis patients with biopsy proven NAFLD. Results: Based on histories, laboratory tests, and ultrasound studies, 84 (59.2%) received clinical diagnosis of NAFLD; 30 had factors potentially associated with liver disease other than NAFLD (e.g., viral hepatitis, significant ethanol, methotrexate use); and 28 (19.7%) had normal livers. Comparison of the normal-liver and NAFLD subgroups revealed that NAFLD in psoriasis patients (Ps-NAFLD) was significantly correlated with metabolic syndrome (p <0.05); obesity (p =0.043); hypercholesterolemia (p =0.029); hypertriglyceridemia (p <0.001); AST/ALT ratio >1 (p =0.019), and psoriatic arthritis (PsA) (p =0.036). The association with PsA remained significant after logistic regression analysis (OR=3.94 [CI, 1.07–14.46]). Compared with the retrospective non-psoriatic NAFLD cohort (controls), Ps-NAFLD patients (cases) were likely to have severe NAFLD reflected by non-invasive NAFLD Fibrosis Scores and AST/ALT >1. Conclusions: NAFLD is highly prevalent among psoriasis patients, where it is closely associated with obesity (overall and abdominal), metabolic syndrome, and PsA, and more likely to cause severe liver fibrosis (compared with nonPs-NAFLD). Routine work-up for NAFLD may be warranted in patients with psoriasis, especially when potentially hepatotoxic drug therapy is being considered. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
10. Acute hepatitis caused by a natural lipid-lowering product: When “alternative” medicine is no “alternative” at all
- Author
-
Grieco, Antonio, Miele, Luca, Pompili, Maurizio, Biolato, Marco, Vecchio, Fabio M., Grattagliano, Ignazio, and Gasbarrini, Giovanni
- Subjects
- *
HEPATITIS , *ANTILIPEMIC agents , *DRUG side effects , *ALTERNATIVE medicine , *HYPERCHOLESTEREMIA , *DISEASES in older women , *LIVER function tests , *CORONARY disease - Abstract
Background/Aims: The general public’s growing mistrust of the pharmaceutical industry and its perception of the lack of adverse effects of “natural” therapy have lead to the increasing use of “alternative drugs” for hypercholesterolemia. Methods: A sixty-three year old woman presented with severe hypertransaminasemia that had developed progressively over a few weeks. For six months she had been taking Equisterol®, an over-the-counter lipid-lowering product containing guggulsterol and red yeast rice extract. The product had been prescribed for hypercholesterolemia because the patient had developed hepatotoxicity while on lovastatin. Results: Liver biopsy revealed severe lobular necroinflammatory changes with an eosinophilic infiltrate. The episode was regarded as an adverse drug reaction after exclusion of other possible causes of acute liver disease and the prompt normalization of liver function tests after Equisterol® had been discontinued. Red yeast rice extract’s cholesterol-lowering properties are largely due to fungal metabolites known as monacolins, one of which – monacolin K – is identical to lovastatin. Conclusions: The choice of an alternative medicine approach in this case subjected the patient to “re-challenge” with the official medicine agent that had previously caused mild hepatotoxicity. Physicians should keep in mind that “alternative” medicine is not always the safest alternative and sometimes it is not even “alternative.” [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
11. Severe veno-occlusive disease after autologous peripheral blood stem cell transplantation for high-grade non-Hodgkin lymphoma: report of a successfully managed case and a literature review of veno-occlusive disease.
- Author
-
Palladino, Mariangela, Miele, Luca, Pompili, Maurizio, Forgione, Alessandra, Vellone, Valerio, Vecchio, Fabio M., Chiusolo, Patrizia, Laurenti, Luca, Gasbarrini, Giovanni, Sica, Simona, and Grieco, Antonio
- Subjects
- *
DRUG therapy , *HOMOGRAFTS , *STEM cell transplantation , *B cells , *LYMPHOMAS - Abstract
Veno-occlusive disease (VOD) of the liver is a severe complication of high-dose chemotherapy and allogeneic or autologous stem cell transplantation with potential fatal outcome. We report a case of severe VOD in a patient with a high-grade B-cell lymphoma. Liver-venule occlusion was confirmed by liver biopsy. Supportive care, fibrinolytic treatment with recombinant tissue plasminogen activator and defibrotide maintenance therapy led to complete resolution of VOD demonstrated at liver biopsy and with a follow-up of 44 months after autologous peripheral blood stem cell transplantation. The literature on VOD has been reviewed. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
12. Socio-demographic determinants of coinfections by HIV, hepatitis B and hepatitis C viruses in central Italian prisoners.
- Author
-
La Torre, Giuseppe, Miele, Luca, Chiaradia, Giacomina, Mannocci, Alice, Reali, Manuela, Gasbarrini, Giovanni, De Vito, Elisabetta, Grieco, Antonio, and Ricciardi, Walter
- Subjects
- *
HIV infections , *HEPATITIS B , *HEPATITIS C , *PRISONERS , *DISEASES - Abstract
Background: The coinfections HIV/HCV/HBV are an important health issue in penitentiary communities. The aim of the study was to examine HIV, HBV and HCV coinfections determinants amongst prisoners in the jails of Southern Lazio (Central Italy), in the period 1995-2000. Methods: Diagnosis of seropositivities for HIV, HBV and HCV was made using ELISA method. A multiple logistic regression analysis was conducted to verify the influence of socio-demographic factors on the HIV/HBV/HCV coinfections. Results: HIV/HCV, HBV/HCV and HIV/HBV coinfections were detected in 42 (4%), 203 (17.9%) and 31 (2.9%)inmates, respectively. These coinfections are significantly associated with the status of drug addiction (OR = 16.02; p = 0.012; OR = 4.15; p < 0.001; OR = 23.57; p = 0.002), smoking habits (OR = 3.73; p = 0.033; OR = 1.42; p = 0.088; OR = 4.25; p = 0.053) and Italian nationality (OR = 7.05; p = 0.009; OR = 2.31; p < 0.001; OR = 4.61; p = 0.04). Conclusion: The prevalence of HIV, HBV and HCV seropositivity in jails suggests that information and education programs for inmates could be useful to reduce the spread of such infections. [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
13. Correlates of HCV seropositivity among familial contacts of HCV positive patients.
- Author
-
la Torre, Giuseppe, Miele, Luca, Mannocci, Alice, Chiaradia, Giacomina, Berloco, Filippo, Gabrieli, Maria L., Gasbarrini, Giovanni, Ficarra, Maria Giovanna, Matera, Antonio, Ricciardi, Gualtiero, and Grieco, Antonio
- Subjects
- *
DETERMINANTS (Mathematics) , *HEPATITIS C , *FAMILIAL diseases , *MULTIVARIATE analysis , *SEXUAL intercourse - Abstract
Background: Determinants of intrafamilial HCV transmission are still being debated. The aim of this study is to investigate the correlates of HCV seropositivity among familial contacts of HCV positive patients in Italy. Methods: A cross-sectional study was conducted with 175 HCV positive patients (index cases), recruited from Policlinico Gemelli in Rome as well as other hospitals in Central Italy between 1995 and 2000 (40% female, mean age 57 ± 15.2 years), and 259 familial contacts. Differences in proportions of qualitative variables were tested with non-parametric tests (χ2, Yates correction, Fisher exact test), and a p value < 0.05 was considered significant. A multivariate analysis was conducted using logistic regression in order to verify which variables statistically have an influence on HCV positivity in contact individuals. Results: Seropositivity for HCV was found in 8.9% of the contacts. From the univariate analysis, risk factors significantly associated to HCV positivity in the contacts were: intravenous drug addiction (p = 0.004) and intercourse with drug addicts (p = 0.005). The only variables associated significantly and independently to HCV seropositivity in patients' contacts were intercourse with drug addicts (OR = 19.28; 95% CI: 2.01 - 184.94), the retirement status from work (OR = 3.76; 95% CI: 1.17 - 11.98), the time of the relationship (OR = 1.06; 95% CI: 1.00 - 1.11) and tattoos (OR = 7.68; 95% CI: 1.00 - 60.20). Conclusion: The present study confirms that having intercourse with a drug addict is the most significant risk factor for intrafamilial HCV transmission. The association with retirement status from work could be related to both a long-term relationship with an index case and past exposure to common risk factors. [ABSTRACT FROM AUTHOR]
- Published
- 2006
- Full Text
- View/download PDF
14. A Role for the Biological Clock in Liver Cancer.
- Author
-
Mazzoccoli, Gianluigi, Miele, Luca, Marrone, Giuseppe, Mazza, Tommaso, Vinciguerra, Manlio, and Grieco, Antonio
- Subjects
- *
BIOLOGICAL rhythms , *CELLULAR signal transduction , *CIRCADIAN rhythms , *CLINICAL chronobiology , *FATTY liver , *HEPATOCELLULAR carcinoma , *CIRRHOSIS of the liver , *FIBROSIS , *DISEASE progression , *CHRONOBIOLOGY disorders , *DISEASE complications , *DISEASE risk factors - Abstract
The biological clock controls at the molecular level several aspects of mammalian physiology, by regulating daily oscillations of crucial biological processes such as nutrient metabolism in the liver. Disruption of the circadian clock circuitry has recently been identified as an independent risk factor for cancer and classified as a potential group 2A carcinogen to humans. Hepatocellular carcinoma (HCC) is the prevailing histological type of primary liver cancer, one of the most important causes of cancer-related death worldwide. HCC onset and progression is related to B and C viral hepatitis, alcoholic and especially non-alcoholic fatty liver disease (NAFLD)-related milieu of fibrosis, cirrhosis, and chronic inflammation. In this review, we recapitulate the state-of-the-art knowledge on the interplay between the biological clock and the oncogenic pathways and mechanisms involved in hepatocarcinogenesis. Finally, we propose how a deeper understanding of circadian clock circuitry–cancer pathways' crosstalk is promising for developing new strategies for HCC prevention and management. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
15. Evaluation of ChatGPT as a Counselling Tool for Italian-Speaking MASLD Patients: Assessment of Accuracy, Completeness and Comprehensibility.
- Author
-
Pugliese, Nicola, Polverini, Davide, Lombardi, Rosa, Pennisi, Grazia, Ravaioli, Federico, Armandi, Angelo, Buzzetti, Elena, Dalbeni, Andrea, Liguori, Antonio, Mantovani, Alessandro, Villani, Rosanna, Gardini, Ivan, Hassan, Cesare, Valenti, Luca, Miele, Luca, Petta, Salvatore, Sebastiani, Giada, and Aghemo, Alessio
- Subjects
- *
CHATGPT , *ARTIFICIAL intelligence , *COUNSELING , *CHATBOTS , *PHYSICAL activity - Abstract
Background: Artificial intelligence (AI)-based chatbots have shown promise in providing counseling to patients with metabolic dysfunction-associated steatotic liver disease (MASLD). While ChatGPT3.5 has demonstrated the ability to comprehensively answer MASLD-related questions in English, its accuracy remains suboptimal. Whether language influences these results is unclear. This study aims to assess ChatGPT's performance as a counseling tool for Italian MASLD patients. Methods: Thirteen Italian experts rated the accuracy, completeness and comprehensibility of ChatGPT3.5 in answering 15 MASLD-related questions in Italian using a six-point accuracy, three-point completeness and three-point comprehensibility Likert's scale. Results: Mean scores for accuracy, completeness and comprehensibility were 4.57 ± 0.42, 2.14 ± 0.31 and 2.91 ± 0.07, respectively. The physical activity domain achieved the highest mean scores for accuracy and completeness, whereas the specialist referral domain achieved the lowest. Overall, Fleiss's coefficient of concordance for accuracy, completeness and comprehensibility across all 15 questions was 0.016, 0.075 and −0.010, respectively. Age and academic role of the evaluators did not influence the scores. The results were not significantly different from our previous study focusing on English. Conclusion: Language does not appear to affect ChatGPT's ability to provide comprehensible and complete counseling to MASLD patients, but accuracy remains suboptimal in certain domains. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
16. Machine learning approaches to enhance diagnosis and staging of patients with MASLD using routinely available clinical information.
- Author
-
McTeer, Matthew, Applegate, Douglas, Mesenbrink, Peter, Ratziu, Vlad, Schattenberg, Jörn M., Bugianesi, Elisabetta, Geier, Andreas, Romero Gomez, Manuel, Dufour, Jean-Francois, Ekstedt, Mattias, Francque, Sven, Yki-Jarvinen, Hannele, Allison, Michael, Valenti, Luca, Miele, Luca, Pavlides, Michael, Cobbold, Jeremy, Papatheodoridis, Georgios, Holleboom, Adriaan G., and Tiniakos, Dina
- Subjects
- *
SUPERVISED learning , *MACHINE learning , *METABOLIC disorders , *LIVER diseases , *PREDICTION models - Abstract
Aims: Metabolic dysfunction Associated Steatotic Liver Disease (MASLD) outcomes such as MASH (metabolic dysfunction associated steatohepatitis), fibrosis and cirrhosis are ordinarily determined by resource-intensive and invasive biopsies. We aim to show that routine clinical tests offer sufficient information to predict these endpoints. Methods: Using the LITMUS Metacohort derived from the European NAFLD Registry, the largest MASLD dataset in Europe, we create three combinations of features which vary in degree of procurement including a 19-variable feature set that are attained through a routine clinical appointment or blood test. This data was used to train predictive models using supervised machine learning (ML) algorithm XGBoost, alongside missing imputation technique MICE and class balancing algorithm SMOTE. Shapley Additive exPlanations (SHAP) were added to determine relative importance for each clinical variable. Results: Analysing nine biopsy-derived MASLD outcomes of cohort size ranging between 5385 and 6673 subjects, we were able to predict individuals at training set AUCs ranging from 0.719-0.994, including classifying individuals who are At-Risk MASH at an AUC = 0.899. Using two further feature combinations of 26-variables and 35-variables, which included composite scores known to be good indicators for MASLD endpoints and advanced specialist tests, we found predictive performance did not sufficiently improve. We are also able to present local and global explanations for each ML model, offering clinicians interpretability without the expense of worsening predictive performance. Conclusions: This study developed a series of ML models of accuracy ranging from 71.9—99.4% using only easily extractable and readily available information in predicting MASLD outcomes which are usually determined through highly invasive means. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
17. Therapeutic Approach to Post-Transplant Recurrence of Hepatocellular Carcinoma: Certainties and Open Issues.
- Author
-
Marrone, Giuseppe, Leone, Maria Sandrina, Biolato, Marco, Liguori, Antonio, Bianco, Giuseppe, Spoletini, Gabriele, Gasbarrini, Antonio, Miele, Luca, and Pompili, Maurizio
- Subjects
- *
PILOT projects , *LIVER tumors , *CANCER relapse , *MTOR inhibitors , *UNCERTAINTY , *IMMUNOSUPPRESSION , *POSTOPERATIVE period , *LIVER transplantation , *HEPATOCELLULAR carcinoma - Abstract
Simple Summary: Hepatocellular carcinoma (HCC) recurrence after liver transplantation (LT) results in a relevant worsening of the prognosis of transplanted subjects. Pre-transplant HCC characteristics are the main determinants of the risk of recurrence and various tools exist to estimate recurrence risk. Once recurrence has occurred, the pattern of recurrence greatly influences whether the patient is a candidate for curative treatment and consequently significantly impacts prognosis. We reviewed different predictive models of post-transplant recurrence, the role of immunosuppression, and the efficacy and feasibility of various therapeutic approaches. Hepatocellular carcinoma (HCC) is a growing indication for liver transplantation (LT). Careful candidate selection is a prerequisite to keep post-LT recurrence rates within acceptable percentages. In the pre-LT period, various types of locoregional treatments and/or systemic therapies can be used for bridging or downstaging purposes. In this context, one of the factors limiting the possibility of treatment is the degree of functional liver impairment. In the LT subject, no widely accepted indications are available to guide treatment of disease recurrence and heterogeneity exists between transplant centers. Improved liver function post LT makes multiple therapeutic strategies theoretically feasible, but patient management is complicated by the need to adjust immunosuppressive therapy and to assess potential toxicities and drug–drug interactions. Finally, there is controversy and uncertainty about the use of recently introduced immunotherapeutic drugs, mainly due to the risk of organ rejection. In this paper, we will review the most recent available literature on the management of post-transplant HCC recurrence, discussing evidence and controversies. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
18. The Liver in Heart Failure: From Biomarkers to Clinical Risk.
- Author
-
Aspromonte, Nadia, Fumarulo, Isabella, Petrucci, Lucrezia, Biferali, Bianca, Liguori, Antonio, Gasbarrini, Antonio, Massetti, Massimo, and Miele, Luca
- Subjects
- *
LIVER failure , *HEART failure , *HEART diseases , *HEART , *BIOMARKERS , *DISEASE management - Abstract
Heart failure (HF) is a clinical syndrome due to heart dysfunction, but in which other organs are also involved, resulting in a complex multisystemic disease, burdened with high mortality and morbidity. This article focuses on the mutual relationship between the heart and liver in HF patients. Any cause of right heart failure can cause hepatic congestion, with important prognostic significance. We have analyzed the pathophysiology underlying this double interaction. Moreover, we have explored several biomarkers and non-invasive tests (i.e., liver stiffness measurement, LSM) potentially able to provide important support in the management of this complex disease. Cardiac biomarkers have been studied extensively in cardiology as a non-invasive diagnostic and monitoring tool for HF. However, their usefulness in assessing liver congestion in HF patients is still being researched. On the other hand, several prognostic scores based on liver biomarkers in patients with HF have been proposed in recent years, recognizing the important burden that liver involvement has in HF. We also discuss the usefulness of a liver stiffness measurement (LSM), which has been recently proposed as a reliable and non-invasive method for assessing liver congestion in HF patients, with therapeutic and prognostic intentions. Lastly, the relationship between LSM and biomarkers of liver congestion is not clearly defined; more research is necessary to establish the clinical value of biomarkers in assessing liver congestion in HF patients and their relationship with LSM. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
19. Hepatic mitochondrial beta-oxidation in patients with nonalcoholic steatohepatitis assessed by 13C-octanoate breath test
- Author
-
Miele, Luca, Grieco, Antonio, Armuzzi, Alessandro, Candelli, Marcello, Forgione, Alessandra, Gasbarrini, Antonio, and Gasbarrini, Giovanni
- Published
- 2003
- Full Text
- View/download PDF
20. Urinary lithogenic profile of patients with non-alcoholic fatty liver disease.
- Author
-
Bargagli, Matteo, Liguori, Antonio, Napodano, Cecilia, Baroni, Silvia, Tomasello, Lidia, Pizzolante, Fabrizio, Matthaeis, Nicoletta De, Ninno, Grazia De, Grieco, Antonio, Gasbarrini, Antonio, Gambaro, Giovanni, Ferraro, Pietro Manuel, and Miele, Luca
- Subjects
- *
FATTY liver , *NON-alcoholic fatty liver disease , *KIDNEY stones - Abstract
Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease, ranging from pure steatosis to non-alcoholic steatohepatitis and ultimately to liver cirrhosis. In our study, adult NAFLD patients did not have different oxalate excretion values [ -0.26 (95% CI -1.59-1.08), I P i =.681] and only altered urinary ammonium and magnesium excretions were found as proposed risk factors for nephrolithiasis (Fig. Our findings indicate the need for further prospective studies to compare the characteristics of NAFLD patients with and without nephrolithiasis and its incidence at different degrees of NAFLD severity to expand on the observations reported here. [Extracted from the article]
- Published
- 2023
- Full Text
- View/download PDF
21. Corrigendum to “Acute hepatitis caused by a natural lipid-lowering product: When “alternative” medicine is no “alternative” at all” [J Hepatol 50 (2009) 1273–1277]
- Author
-
Grieco, Antonio, Miele, Luca, Pompili, Maurizio, Biolato, Marco, Vecchio, Fabio M., Grattagliano, Ignazio, and Gasbarrini, Giovanni
- Published
- 2010
- Full Text
- View/download PDF
22. LIVER FUNCTION TEST DURING METFORMIN THERAPY IN PATIENTS WITH POLYCYSTIC OVARY SYNDROME (PCOS)
- Author
-
Miele, Luca, Cefalo, Consuelo, Martinez, Daniela, Forgione, Alessandra, Pompili, Maurizio, Sagnella, Francesca, Racco, Simona, Apa, Rosanna, Gasbarrini, Giovanni, and Grieco, Antonio
- Published
- 2008
- Full Text
- View/download PDF
23. NON-INVASIVE ASSESSMENT OF HISTOLOGICAL INFLAMMATION IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD)
- Author
-
Forgione, Alessandra, Miele, Luca, Cefalo, Consuelo, Caprodossi, Anna, Vellone, Valerio, Racco, Simona, Gabrieli, Maria L., Vero, Vittoria, Biolato, Marco, Vecchio, Fabio M., Gasbarrini, Giovanni, and Grieco, Antonio
- Published
- 2008
- Full Text
- View/download PDF
24. TOP-144-YI Heterozygosity for rare Apolipoprotein B variants predispose to severe metabolic associated steatotic liver disease.
- Author
-
Mureddu, Matteo, Pelusi, Serena, Ronzoni, Luisa, Malvestiti, Francesco, Moretti, Vittoria, Eigadeh, Hadi, Soardo, Giorgio, Federico, Alessandro, Russo, Francesco Paolo, Fracanzani, Anna Ludovica, Vespasiani-Gentilucci, Umberto, Miele, Luca, Bugianesi, Elisabetta, D'Ambrosio, Roberta, Petta, Salvatore, Fraquelli, Mirella, Prati, Daniele, and Valenti, Luca
- Published
- 2024
- Full Text
- View/download PDF
25. Rare ATG7 genetic variants predispose patients to severe fatty liver disease.
- Author
-
Baselli, Guido A., Jamialahmadi, Oveis, Pelusi, Serena, Ciociola, Ester, Malvestiti, Francesco, Saracino, Marco, Santoro, Luigi, Cherubini, Alessandro, Dongiovanni, Paola, Maggioni, Marco, Bianco, Cristiana, Tavaglione, Federica, Cespiati, Annalisa, Mancina, Rosellina M., D'Ambrosio, Roberta, Vaira, Valentina, Petta, Salvatore, Miele, Luca, Vespasiani-Gentilucci, Umberto, and Federico, Alessandro
- Subjects
- *
GENETIC variation , *NON-alcoholic fatty liver disease , *FATTY liver , *HEPATIC fibrosis , *IMMOBILIZED proteins , *LIVER diseases - Abstract
Non-alcoholic fatty liver disease (NAFLD) is the leading cause of liver disorders and has a strong heritable component. The aim of this study was to identify new loci that contribute to severe NAFLD by examining rare variants. We performed whole-exome sequencing in individuals with NAFLD and advanced fibrosis or hepatocellular carcinoma (n = 301) and examined the enrichment of likely pathogenic rare variants vs. the general population. This was followed by validation at the gene level. In patients with severe NAFLD, we observed an enrichment of the p.P426L variant (rs143545741 C>T; odds ratio [OR] 5.26, 95% CI 2.1-12.6; p = 0.003) of autophagy-related 7 (ATG7) , which we characterized as a loss-of-function, vs. the general population, and an enrichment in rare variants affecting the catalytic domain (OR 13.9; 95% CI 1.9-612; p = 0.002). In the UK Biobank cohort, loss-of-function ATG7 variants increased the risk of cirrhosis and hepatocellular carcinoma (OR 3.30; 95% CI 1.1-7.5 and OR 12.30, 95% CI 2.6-36, respectively; p < 0.001 for both). The low-frequency loss-of-function p.V471A variant (rs36117895 T>C) was also associated with severe NAFLD in the clinical cohort (OR 1.7; 95% CI 1.2-2.5; p = 0.003), predisposed to hepatocellular ballooning (p = 0.007) evolving to fibrosis in the Liver biopsy cohort (n = 2,268), and was associated with liver injury in the UK Biobank (aspartate aminotransferase levels, p < 0.001), with a larger effect in severely obese individuals in whom it was linked to hepatocellular carcinoma (p = 0.009). ATG7 protein localized to periportal hepatocytes, particularly in the presence of ballooning. In the Liver Transcriptomic cohort (n = 125), ATG7 expression correlated with suppression of the TNFα pathway, which was conversely upregulated in p.V471A carriers. We identified rare and low-frequency ATG7 loss-of-function variants that promote NAFLD progression by impairing autophagy and facilitating ballooning and inflammation. We found that rare mutations in a gene called autophagy-related 7 (ATG7) increase the risk of developing severe liver disease in individuals with dysmetabolism. These mutations cause an alteration in protein function and impairment of self-renewal of cellular content, leading to liver damage and inflammation. [Display omitted] • NAFLD is the leading cause of liver disorders and has a strong heritable component. • Rare loss-of-function ATG7 gene mutations increase the risk of severe liver disease in patients with NAFLD. • ATG7 mutations cause altered protein function and impairment of autophagy, leading to hepatocellular ballooning and inflammation. • The most frequent variant is responsible for a meaningful fraction of predisposition to ballooning and hepatocellular carcinoma. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
26. Machine Learning-Assisted FTIR Analysis of Circulating Extracellular Vesicles for Cancer Liquid Biopsy.
- Author
-
Di Santo, Riccardo, Vaccaro, Maria, Romanò, Sabrina, Di Giacinto, Flavio, Papi, Massimiliano, Rapaccini, Gian Ludovico, De Spirito, Marco, Miele, Luca, Basile, Umberto, and Ciasca, Gabriele
- Subjects
- *
ALPHA fetoproteins , *EXTRACELLULAR vesicles , *FISHER discriminant analysis , *FOURIER transform infrared spectroscopy , *TUMOR markers , *VITAMIN K , *HYPERSPECTRAL imaging systems - Abstract
Extracellular vesicles (EVs) are abundantly released into the systemic circulation, where they show remarkable stability and harbor molecular constituents that provide biochemical information about their cells of origin. Due to this characteristic, EVs are attracting increasing attention as a source of circulating biomarkers for cancer liquid biopsy and personalized medicine. Despite this potential, none of the discovered biomarkers has entered the clinical practice so far, and novel approaches for the label-free characterization of EVs are highly demanded. In this regard, Fourier Transform Infrared Spectroscopy (FTIR) has great potential as it provides a quick, reproducible, and informative biomolecular fingerprint of EVs. In this pilot study, we investigated, for the first time in the literature, the capability of FTIR spectroscopy to distinguish between EVs extracted from sera of cancer patients and controls based on their mid-IR spectral response. For this purpose, EV-enriched suspensions were obtained from the serum of patients diagnosed with Hepatocellular Carcinoma (HCC) of nonviral origin and noncancer subjects. Our data point out the presence of statistically significant differences in the integrated intensities of major mid-IR absorption bands, including the carbohydrate and nucleic acids band, the protein amide I and II bands, and the lipid CH stretching band. Additionally, we used Principal Component Analysis combined with Linear Discriminant Analysis (PCA-LDA) for the automated classification of spectral data according to the shape of specific mid-IR spectral signatures. The diagnostic performances of the proposed spectral biomarkers, alone and combined, were evaluated using multivariate logistic regression followed by a Receiving Operator Curve analysis, obtaining large Areas Under the Curve (AUC = 0.91, 95% CI 0.81–1.0). Very interestingly, our analyses suggest that the discussed spectral biomarkers can outperform the classification ability of two widely used circulating HCC markers measured on the same groups of subjects, namely alpha-fetoprotein (AFP), and protein induced by the absence of vitamin K or antagonist-II (PIVKA-II). [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
27. WED-215 HeparDx™ (by Metadeq, Inc.) is a reliable biomarker-based non-invasive test for MASH, capable of detecting the presence of inflammation and ballooning.
- Author
-
Angelini, Giulia, Russo, Sara, Lembo, Erminia, Verrastro, Ornella, Guidone, Caterina, Liguori, Antonio, Harrison, Stephen A., Trylesinski, Aldo, Miele, Luca, and Mingrone, Geltrude
- Published
- 2024
- Full Text
- View/download PDF
28. FRI-290 Evaluation of ChatGPT as a counselling tool for Italian-speaking MASLD patients: assessment of accuracy, completeness and comprehensiveness.
- Author
-
Pugliese, Nicola, Polverini, Davide, Lombardi, Rosa, Pennisi, Grazia, Ravaioli, Federico, Armandi, Angelo, Buzzetti, Elena, Dalbeni, Andrea, Liguori, Antonio, Mantovani, Alessandro, Villani, Rosanna, Hassan, Cesare, Valenti, Luca, Miele, Luca, Petta, Salvatore, Sebastiani, Giada, and Aghemo, Alessio
- Published
- 2024
- Full Text
- View/download PDF
29. TOP-301 Impact of clonal hematopoiesis of indeterminate potential on hepatocellular carcinoma in steatotic liver disease.
- Author
-
Pelusi, Serena, Marchetti, Alfredo, Malvestiti, Francesco, Ricchiuti, Antony, Ronzoni, Luisa, Lionetti, Marta, Moretti, Vittoria, Bugianesi, Elisabetta, Miele, Luca, Gentilucci, Umberto Vespasiani, Dongiovanni, Paola, Federico, Alessandro, Soardo, Giorgio, D'Ambrosio, Roberta, Reeves, Helen Louise, La Mura, Vincenzo, Prati, Daniele, Bolli, Niccolò, and Valenti, Luca
- Published
- 2024
- Full Text
- View/download PDF
30. Solving the mystery of HBV-related mixed cryoglobulinemia: potential biomarkers of disease progression.
- Author
-
Pocino, Krizia, Napodano, Cecilia, Gragnani, Laura, Ciasca, Gabriele, Colantuono, Stefania, Marri, Silvia, Vantaggio, Lorenzo, Gulli, Francesca, Lorini, Serena, Barini, Antonella, Stefanile, Annunziata, Miele, Luca, Casato, Milvia, Zignego, Anna Linda, Rapaccini, Gian Ludovico, Marino, Mariapaola, Visentini, Marcella, and Basile, Umberto
- Subjects
- *
BIOMARKERS , *HEPATITIS B , *DISEASE progression , *IMMUNOGLOBULINS , *CONFIDENCE intervals , *HEMOSTASIS , *RETROSPECTIVE studies , *MANN Whitney U Test , *DESCRIPTIVE statistics , *VASCULAR diseases , *DATA analysis software , *LOGISTIC regression analysis , *DISEASE complications - Abstract
Objectives The biomarkers of an immunological dysregulation due to a chronic HBV infection are indeed understudied. If untreated, this condition may evolve into liver impairment co-occurring with extrahepatic involvements. Here, we aim to identify a new panel of biomarkers [including immunoglobulin G (IgG) subclasses, RF, and Free Light Chains (FLCs)] that may be useful and reliable for clinical evaluation of HBV-related cryoglobulinemia. Methods We retrospectively analysed clinical data from 44 HBV-positive patients. The patients were stratified (according to the presence/absence of mixed cryoglobulinemia) into two groups: 22 with cryoglobulins (CGs) and 22 without CGs. Samples from 20 healthy blood donors (HDs) were used as negative controls. Serum samples were tested for IgG subclasses, RF (-IgM, -IgG, and -IgA type), and FLCs. Results We detected a strikingly different distribution of serum IgG subclasses between HDs and HBV-positive patients, together with different RF isotypes; in addition, FLCs were significantly increased in HBV-positive patients compared with HDs, while no significant difference was shown between HBV-positive patients with/without mixed cryoglobulinemia. Conclusion The immune-inflammatory response triggered by HBV may be monitored by a peculiar profile of biomarkers. Our results open a new perspective in the precision medicine era; in these challenging times, they could also be employed to monitor the clinical course of those COVID-19 patients who are at high risk of HBV reactivation due to liver impairment and/or immunosuppressive therapies. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
31. Mistranslation Drives Alterations in Protein Levels and the Effects of a Synonymous Variant at the Fibroblast Growth Factor 21 Locus.
- Author
-
Bayoumi, Ali, Elsayed, Asmaa, Han, Shuanglin, Petta, Salvatore, Adams, Leon A., Aller, Rocio, Khan, Anis, García‐Monzón, Carmelo, Arias‐Loste, María Teresa, Miele, Luca, Latchoumanin, Olivier, Alenizi, Shafi, Gallego‐Durán, Rocio, Fischer, Janett, Berg, Thomas, Craxì, Antonio, Metwally, Mayada, Qiao, Liang, Liddle, Christopher, and Yki‐Järvinen, Hannele
- Subjects
- *
FIBROBLAST growth factors , *FATTY liver , *PROTEINS , *METABOLIC disorders - Abstract
Fibroblast growth factor 21 (FGF21) is a liver‐derived hormone with pleiotropic beneficial effects on metabolism. Paradoxically, FGF21 levels are elevated in metabolic diseases. Interventions that restore metabolic homeostasis reduce FGF21. Whether abnormalities in FGF21 secretion or resistance in peripheral tissues is the initiating factor in altering FGF21 levels and function in humans is unknown. A genetic approach is used to help resolve this paradox. The authors demonstrate that the primary event in dysmetabolic phenotypes is the elevation of FGF21 secretion. The latter is regulated by translational reprogramming in a genotype‐ and context‐dependent manner. To relate the findings to tissues outcomes, the minor (A) allele of rs838133 is shown to be associated with increased hepatic inflammation in patients with metabolic associated fatty liver disease. The results here highlight a dominant role for translation of the FGF21 protein to explain variations in blood levels that is at least partially inherited. These results provide a framework for translational reprogramming of FGF21 to treat metabolic diseases. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
32. Inflammatory Mechanisms Underlying Nonalcoholic Steatohepatitis and the Transition to Hepatocellular Carcinoma.
- Author
-
Peiseler, Moritz, Tacke, Frank, Miele, Luca, and Reeves, Helen L.
- Subjects
- *
NON-alcoholic fatty liver disease , *INFLAMMATION , *LEUCOCYTES , *GUT microbiome , *MACROPHAGES , *PARADIGMS (Social sciences) , *IMMUNITY , *HEPATOCELLULAR carcinoma , *IMMUNOTHERAPY , *ADIPOSE tissues , *DISEASE complications - Abstract
Simple Summary: Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease affecting a quarter of the global population and carries the risk of developing malignant liver cancer. Inflammation is considered paramount in the progression of the disease and many different immune cells and pathways have been implicated in the development of NAFLD. Novel techniques in basic immunology have substantially enhanced the possibilities to study inflammation and the heterogeneity of immune cells. Based on recent studies, we provide a review of novel paradigms emerging in steatohepatitis and the development of hepatocellular carcinoma and outline the multifaceted contributions of immunity to advancing NAFLD. End-stage NAFLD with liver cancer has an abysmal prognosis and effective medical therapies are lacking, therefore a better understanding of the disease mechanisms will ultimately help to improve patients' care. Nonalcoholic fatty liver disease (NAFLD) is a rising chronic liver disease and comprises a spectrum from simple steatosis to nonalcoholic steatohepatitis (NASH) to end-stage cirrhosis and risk of hepatocellular carcinoma (HCC). The pathogenesis of NAFLD is multifactorial, but inflammation is considered the key element of disease progression. The liver harbors an abundance of resident immune cells, that in concert with recruited immune cells, orchestrate steatohepatitis. While inflammatory processes drive fibrosis and disease progression in NASH, fueling the ground for HCC development, immunity also exerts antitumor activities. Furthermore, immunotherapy is a promising new treatment of HCC, warranting a more detailed understanding of inflammatory mechanisms underlying the progression of NASH and transition to HCC. Novel methodologies such as single-cell sequencing, genetic fate mapping, and intravital microscopy have unraveled complex mechanisms behind immune-mediated liver injury. In this review, we highlight some of the emerging paradigms, including macrophage heterogeneity, contributions of nonclassical immune cells, the role of the adaptive immune system, interorgan crosstalk with adipose tissue and gut microbiota. Furthermore, we summarize recent advances in preclinical and clinical studies aimed at modulating the inflammatory cascade and discuss how these novel therapeutic avenues may help in preventing or combating NAFLD-associated HCC. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
33. Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores.
- Author
-
Bianco, Cristiana, Jamialahmadi, Oveis, Pelusi, Serena, Baselli, Guido, Dongiovanni, Paola, Zanoni, Irene, Santoro, Luigi, Maier, Silvia, Liguori, Antonio, Meroni, Marica, Borroni, Vittorio, D'Ambrosio, Roberta, Spagnuolo, Rocco, Alisi, Anna, Federico, Alessandro, Bugianesi, Elisabetta, Petta, Salvatore, Miele, Luca, Vespasiani-Gentilucci, Umberto, and Anstee, Quentin M.
- Subjects
- *
NON-alcoholic fatty liver disease , *HEPATOCELLULAR carcinoma , *LIVER cancer , *HIGH-calorie diet - Abstract
Hepatocellular carcinoma (HCC) risk stratification in individuals with dysmetabolism is a major unmet need. Genetic predisposition contributes to non-alcoholic fatty liver disease (NAFLD). We aimed to exploit robust polygenic risk scores (PRS) that can be evaluated in the clinic to gain insight into the causal relationship between NAFLD and HCC, and to improve HCC risk stratification. We examined at-risk individuals (NAFLD cohort, n = 2,566; 226 with HCC; and a replication cohort of 427 German patients with NAFLD) and the general population (UK Biobank [UKBB] cohort, n = 364,048; 202 with HCC). Variants in PNPLA3-TM6SF2-GCKR-MBOAT7 were combined in a hepatic fat PRS (PRS-HFC), and then adjusted for HSD17B13 (PRS-5). In the NAFLD cohort, the adjusted impact of genetic risk variants on HCC was proportional to the predisposition to fatty liver (p = 0.002) with some heterogeneity in the effect. PRS predicted HCC more robustly than single variants (p < 10-13). The association between PRS and HCC was mainly mediated through severe fibrosis, but was independent of fibrosis in clinically relevant subgroups, and was also observed in those without severe fibrosis (p < 0.05). In the UKBB cohort, PRS predicted HCC independently of classical risk factors and cirrhosis (p < 10-7). In the NAFLD cohort, we identified high PRS cut-offs (≥0.532/0.495 for PRS-HFC/PRS-5) that in the UKBB cohort detected HCC with ~90% specificity but limited sensitivity; PRS predicted HCC both in individuals with (p < 10-5) and without cirrhosis (p < 0.05). Our results are consistent with a causal relationship between hepatic fat and HCC. PRS improved the accuracy of HCC detection and may help stratify HCC risk in individuals with dysmetabolism, including those without severe liver fibrosis. Further studies are needed to validate our findings. By analyzing variations in genes that contribute to fatty liver disease, we developed two risk scores to help predict liver cancer in individuals with obesity-related metabolic complications. These risk scores can be easily tested in the clinic. We showed that the risk scores helped to identify the risk of liver cancer both in high-risk individuals and in the general population. [Display omitted] • Genetic predisposition to liver fat accumulation predisposes to cirrhosis and HCC. • Hepatic fat promotes carcinogenesis, partly via fibrosis. • Polygenic risk scores may improve HCC risk stratification during dysmetabolism. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
34. COVID‐19 and hepatic involvement: The liver as a main actor of the pandemic novel.
- Author
-
Napodano, Cecilia, Pocino, Krizia, Stefanile, Annunziata, Marino, Mariapaola, Miele, Luca, Gulli, Francesca, Basile, Valerio, Pandolfi, Franco, Gasbarrini, Antonio, Rapaccini, Gian Ludovico, and Basile, Umberto
- Subjects
- *
COVID-19 , *PANDEMICS , *SARS-CoV-2 , *LIVER , *THERAPEUTICS - Abstract
In the natural history of SARS‐CoV‐2 infection, liver injury is frequent but quite mild and it is defined as any liver damage occurring during disease progression and treatment of infection in patients with or without pre‐existing liver diseases. The underlying mechanisms for hepatic injury in patients with COVID‐19 are still unclear but the liver damage in SARS‐CoV‐2 infection seems to be directly caused by virus‐induced cytopathic effects. In this review, we will summarize all data of updated literature, regarding the relationship between SARS‐CoV‐2 infection, acute response and liver involvement. An overview will be given on liver injury, liver transplant and the possible consequences of COVID‐19 in patients with pre‐existing liver diseases. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
35. Genetic variation in the TLL1 gene is not associated with fibrosis in patients with metabolic associated fatty liver disease.
- Author
-
Bayoumi, Ali, Jalil, Ismail, Metwally, Mayada, Adams, Leon A., Aller, Rocio, García-Monzón, Carmelo, Arias-Loste, María Teresa, Miele, Luca, Petta, Salvatore, Craxì, Antonio, Gallego-Durán, Rocio, Fischer, Janett, Berg, Thomas, Qiao, Liang, Liddle, Christopher, Bugianesi, Elisabetta, Romero-Gomez, Manuel, George, Jacob, and Eslam, Mohammed
- Subjects
- *
FATTY liver , *FIBROSIS , *JAPANESE people ,WESTERN countries - Abstract
Metabolic associated fatty liver disease (MAFLD) is the most prevalent liver disease in Western nations, with high heritability. A recent study of Japanese patients with the disease suggested that TLL1 rs17047200 is associated with fibrosis; whether a similar association is observed in Caucasian patients with MAFLD is unknown. We investigated the association of the TLL1 rs17047200 polymorphism with liver fibrosis in a cohort of Caucasian patients with MAFLD (n = 728). We also investigated whether TLL1 expression is altered during liver injury in humans, in murine models of fibrosis, and in in-vitro. While TLL1 expression is upregulated in the liver of humans with MAFLD and in mice, the rs17047200 variant was not associated with fibrosis or any other histological features, or with hepatic TLL1 expression. In conclusion, the TLL1 rs17047200 variant is not a risk variant for fibrosis in Caucasian patients with MAFLD. However, TLL1 could be involved in the pathogenesis of liver fibrosis. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
36. Presence of Serum Antinuclear Antibodies Does Not Impact Long-Term Outcomes in Nonalcoholic Fatty Liver Disease.
- Author
-
Younes, Ramy, Govaere, Olivier, Petta, Salvatore, Miele, Luca, Tiniakos, Dina, Burt, Alastair, David, Ezio, Vecchio, Fabio M., Maggioni, Marco, Cabibi, Daniela, Fracanzani, Anna L., Rosso, Chiara, Blanco, Maria J. Garcia, Armandi, Angelo, Caviglia, Gian Paolo, Zaki, Marco Y. W., Liguori, Antonio, Francione, Paolo, Pennisi, Grazia, and Grieco, Antonio
- Subjects
- *
ANTINUCLEAR factors , *LIVER diseases , *CHRONIC active hepatitis , *HEPATOCELLULAR carcinoma , *BIOPSY - Abstract
INTRODUCTION: We investigated the longitudinal impact of antinuclear antibody (ANA) on clinical outcomes and survival in nonalcoholic fatty liver disease (NAFLD). METHODS: ANA were found in 16.9% of 923 biopsy-proven NAFLD patients, but none of them had histologic autoimmune hepatitis (AIH) or developed AIH after a mean follow-up of 106650 months. RESULTS: Although ANA-positive cases had a higher prevalence of nonalcoholic steatohepatitis at baseline, the occurrence of liver-related events, hepatocellula carcinoma, cardiovascular events, extrahepatic malignancy, and overall survival were similar to ANA-negative. DISCUSSION: Once AIH has been ruled out, the long-term outcomes and survival are unaffected by the presence of ANA in patients with NAFLD. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
37. β-Klotho gene variation is associated with liver damage in children with NAFLD.
- Author
-
Dongiovanni, Paola, Crudele, Annalisa, Panera, Nadia, Romito, Ilaria, Meroni, Marica, De Stefanis, Cristiano, Palma, Alessia, Comparcola, Donatella, Fracanzani, Anna Ludovica, Miele, Luca, Valenti, Luca, Nobili, Valerio, and Alisi, Anna
- Subjects
- *
FATTY liver , *FIBROBLAST growth factors , *PEDIATRIC nephrology , *FREE fatty acids , *PATHOLOGY , *JUVENILE diseases - Abstract
• The KLB rs17618244 variant increases the risk of ballooning and lobular inflammation in children with NAFLD. • KLB plasma levels are lower in carriers of the rs17618244 minor A allele. • KLB plasma levels are associated with lobular inflammation, ballooning and fibrosis. • KLB mutant induces intracellular lipid accumulation in HepG2 and Huh7. • KLB mutant causes upregulation of lipotoxic and proinflammatory genes. Non-alcoholic fatty liver disease (NAFLD) is the leading cause of chronic liver disease in adults and children. Along with obesity, diabetes and insulin resistance, genetic factors strongly impact on NAFLD development and progression. Dysregulated bile acid metabolism and the fibroblast growth factor 19 (FGF19) pathway play a pivotal role in NAFLD pathogenesis. However, the mechanism through which the FGF19 receptor system is associated with liver damage in NAFLD remains to be defined. We evaluated the impact of the rs17618244 G>A β-Klotho (KLB) variant on liver damage in 249 pediatric patients with biopsy-proven NAFLD and the association of this variant with the expression of hepatic and soluble KLB. In vitro models were established to investigate the role of the KLB mutant. The KLB rs17618244 variant was associated with an increased risk of ballooning and lobular inflammation. KLB plasma levels were lower in carriers of the rs17618244 minor A allele and were associated with lobular inflammation, ballooning and fibrosis. In HepG2 and Huh7 hepatoma cell lines, exposure to free fatty acids caused a severe reduction of intracellular and secreted KLB. Finally, KLB downregulation obtained by the expression of a KLB mutant in HepG2 and Huh7 cells induced intracellular lipid accumulation and upregulation of p62, ACOX1, ACSL1, IL-1β and TNF-α gene expression. In conclusion, we showed an association between the rs17618244 KLB variant, which leads to reduced KLB expression, and the severity of NAFLD in pediatric patients. We can speculate that the KLB protein may exert a protective role against lipotoxicity and inflammation in hepatocytes. Genetic and environmental factors strongly impact on the pathogenesis and progression of non-alcoholic fatty liver disease (NAFLD). The FGF19/FGFR4/KLB pathway plays a pivotal role in the pathogenesis of NAFLD. The aim of the study was to investigate the impact of a genetic variant in the KLB gene on the severity of liver disease. Our data suggest that the KLB protein plays a protective role against lipotoxicity and inflammation in hepatocytes. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
38. A polymorphism in the Irisin-encoding gene (FNDC5) associates with hepatic steatosis by differential miRNA binding to the 3′UTR.
- Author
-
Metwally, Mayada, Bayoumi, Ali, Romero-Gomez, Manuel, Thabet, Khaled, John, Miya, Adams, Leon A., Huo, Xiaoqi, Aller, Rocio, García-Monzón, Carmelo, Teresa Arias-Loste, María, Bugianesi, Elisabetta, Miele, Luca, Gallego-Durán, Rocio, Fischer, Janett, Berg, Thomas, Liddle, Christopher, Qiao, Liang, George, Jacob, and Eslam, Mohammed
- Subjects
- *
FIBRONECTINS , *FATTY liver , *FATTY degeneration , *SINGLE nucleotide polymorphisms , *GENETIC polymorphisms - Abstract
Graphical abstract Highlights • Irisin, the cleaved extra-cellular fragment of FNDC5 is a myokine thought to have favorable metabolic activity. • The role of variants in the FNDC5 gene in NAFLD is not defined. • Genetic variants in FNDC5 confer risk of human severe hepatic steatosis. • Functional studies reveal that this variant mediates this effect via a miRNA-mediated control of FNDC5 mRNA stability. • Irisin is likely to have a favourable metabolic impact on NAFLD. Background & Aims Irisin, the cleaved extra-cellular fragment of the Fibronectin type III domain-containing protein 5 (FNDC5) is a myokine that is proposed to have favorable metabolic activity. We aimed to elucidate the currently undefined role of variants in the FNDC5 gene in non-alcoholic fatty liver disease (NAFLD). Methods We prioritized single nucleotide polymorphisms in FNDC5 on the basis of their putative biological function and identified rs3480 in the 3′ untranslated region (3′UTR). We studied the association of rs3480 with liver disease severity and the metabolic profile of 987 Caucasian patients with NAFLD. Functional investigations were undertaken using luciferase reporter assays of the 3′UTR of human FNDC5, pyrosequencing for allele-specific expression of FNDC5 in liver, measurement of serum irisin, and bioinformatics analysis. Results The rs3480 (G) allele was associated with advanced steatosis (OR 1.29; 95% CI 1.08–1.55; p = 0.004), but not with other histological features. This effect was independent but additive to PNPLA3 and TM6SF2. The rs3480 polymorphism influenced FNDC5 mRNA stability and the binding of miR-135a-5P. Compared with controls, hepatic expression of this microRNA was upregulated while FNDC5 expression was downregulated. Elevated serum irisin was associated with reduced steatosis, and an improved metabolic profile. Conclusions Carriage of the FNDC5 rs3480 minor (G) allele is associated with more severe steatosis in NAFLD through a microRNA-mediated mechanism controlling FNDC5 mRNA stability. Irisin is likely to have a favorable metabolic impact on NAFLD. Lay summary Irisin is a novel protein produced mainly by muscle, which is known to be released into the circulation, with an unclear role in liver fat deposition. This study demonstrates that genetic variants in the gene encoding the irisin protein modulate the risk of liver fat in patients with fatty liver disease. Interestingly, these effects are independent of, but additive to those of other recently described genetic variants that contribute to liver fat. In functional studies, we have deciphered the detailed molecular mechanisms by which this genetic variant mediates its effects. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
39. Telomerase reverse transcriptase germline mutations and hepatocellular carcinoma in patients with nonalcoholic fatty liver disease.
- Author
-
Donati, Benedetta, Pietrelli, Alessandro, Pingitore, Piero, Dongiovanni, Paola, Caddeo, Andrea, Walker, Lucy, Baselli, Guido, Pelusi, Serena, Rosso, Chiara, Vanni, Ester, Daly, Ann, Mancina, Rosellina Margherita, Grieco, Antonio, Miele, Luca, Grimaudo, Stefania, Craxi, Antonio, Petta, Salvatore, De Luca, Laura, Maier, Silvia, and Soardo, Giorgio
- Subjects
- *
TELOMERASE reverse transcriptase , *LIVER cancer , *FATTY liver , *GENETIC mutation , *GERM cells , *TELOMERES - Abstract
In an increasing proportion of cases, hepatocellular carcinoma (HCC) develops in patients with nonalcoholic fatty liver disease (NAFLD). Mutations in telomerase reverse transcriptase (hTERT) are associated with familial liver diseases. The aim of this study was to examine telomere length and germline hTERT mutations as associated with NAFLD-HCC. In 40 patients with NAFLD-HCC, 45 with NAFLD-cirrhosis and 64 healthy controls, peripheral blood telomere length was evaluated by qRT-PCR and hTERT coding regions and intron-exon boundaries sequenced. We further analyzed 78 patients affected by primary liver cancer (NAFLD-PLC, 76 with HCC). Enrichment of rare coding mutations (allelic frequency <0.001) was evaluated by Burden test. Functional consequences were estimated in silico and by over-expressing protein variants in HEK-293 cells. We found that telomere length was reduced in individuals with NAFLD-HCC versus those with cirrhosis (P = 0.048) and healthy controls (P = 0.0006), independently of age and sex. We detected an enrichment of hTERT mutations in NAFLD-HCC, that was confirmed when we further considered a larger cohort of NAFLD-PLC, and was more marked in female patients (P = 0.03). No mutations were found in cirrhosis and local controls, and only one in 503 healthy Europeans from the 1000 Genomes Project (allelic frequency = 0.025 vs. <0.001; P = 0.0005). Mutations with predicted functional impact, including the frameshift Glu113Argfs*79 and missense Glu668Asp, cosegregated with liver disease in two families. Three patients carried missense mutations (Ala67Val in homozygosity, Pro193Leu and His296Pro in heterozygosity) in the N-terminal template-binding domain (P = 0.037 for specific enrichment). Besides Glu668Asp, the Ala67Val variant resulted in reduced intracellular protein levels. In conclusion, we detected an association between shorter telomeres in peripheral blood and rare germline hTERT mutations and NAFLD-HCC. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
40. The NAFL Risk Score: A simple scoring model to predict 4-y risk for non-alcoholic fatty liver.
- Author
-
Zhou, Yu-Jie, Zheng, Ji-Na, Liu, Wen-Yue, Miele, Luca, Vitale, Alessandro, Van Poucke, Sven, Zou, Tian-Tian, Fang, Dan-Hong, Shen, Shengrong, Zhang, Dong-Chu, and Zheng, Ming-Hua
- Subjects
- *
FATTY liver , *FOLLOW-up studies (Medicine) , *PERIODIC health examinations , *LOGISTIC regression analysis , *RECEIVER operating characteristic curves - Abstract
Background Although several risk factors for non-alcoholic fatty liver (NAFL) have been reported, there are few clinical scores that predict its incidence in the long term. We developed and validate a scoring model for individual prediction of 4-y risk for NAFL. Methods Four-year follow-up data of 8226 initially NAFL-free subjects enrolled for an annual physical examination from Wenzhou Medical Center were analyzed. These subjects are randomly split into the training and the validation cohort. Univariate and multivariable logistic regression models were employed for model development. The selected variables were assigned an integer or half-integer risk score proportional to the estimated coefficient from the logistic model. Risk scores were tested in a validation cohort. We also compared the predictive performance of with that of the NAFLD Index by computing the area under the receiver operating characteristic curve (AUROC). Results The NAFL Risk Score was developed as 0 to 18 points comprising of BMI, TG × GGT, ALT/AST, LDL-C/HDL-C and UA in both sexes. Comparison of the observed with the estimated incidence of NAFL at both cohorts showed satisfactory precision. In addition, the NAFL Risk Score showed relatively good discriminative power (AUROC = 0.739 for males, 0.823 for females) compared with the NAFLD Index (AUROC = 0.661 for males, 0.729 for females) in these Chinese subjects. Conclusions We developed and validated the NAFL Risk Score, a new scoring model to predict 4-y risk for NAFL. The NAFL Risk Score may be clinically simple and useful for assessing individual risk for NAFL. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
41. Pathophysiology of Non Alcoholic Fatty Liver Disease.
- Author
-
Petta, Salvatore, Gastaldelli, Amalia, Rebelos, Eleni, Bugianesi, Elisabetta, Messa, Piergiorgio, Miele, Luca, Svegliati-Baroni, Gianluca, Valenti, Luca, and Bonino, Ferruccio
- Subjects
- *
PATHOLOGICAL physiology , *METABOLIC syndrome , *FATTY liver , *INFLAMMATION , *ADIPOSE tissues - Abstract
The physiopathology of fatty liver and metabolic syndrome are influenced by diet, life style and inflammation, which have a major impact on the severity of the clinicopathologic outcome of non-alcoholic fatty liver disease. A short comprehensive review is provided on current knowledge of the pathophysiological interplay among major circulating effectors/mediators of fatty liver, such as circulating lipids, mediators released by adipose, muscle and liver tissues and pancreatic and gut hormones in relation to diet, exercise and inflammation. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
42. The Metabolic Role of Gut Microbiota in the Development of Nonalcoholic Fatty Liver Disease and Cardiovascular Disease.
- Author
-
Zamparelli, Marco Sanduzzi, Compare, Debora, Coccoli, Pietro, Rocco, Alba, Nardone, Olga Maria, Marrone, Giuseppe, Gasbarrini, Antonio, Grieco, Antonio, Nardone, Gerardo, and Miele, Luca
- Subjects
- *
DISEASE prevalence , *TYPE 2 diabetes , *METABOLIC disorders , *CARDIOVASCULAR diseases risk factors , *HUMAN microbiota - Abstract
The prevalence of metabolic disorders, such as type 2 diabetes (T2D), obesity, and non-alcoholic fatty liver disease (NAFLD), which are common risk factors for cardiovascular disease (CVD), has dramatically increased worldwide over the last decades. Although dietary habit is the main etiologic factor, there is an imperfect correlation between dietary habits and the development of metabolic disease. Recently, research has focused on the role of the microbiome in the development of these disorders. Indeed, gut microbiota is implicated in many metabolic functions and an altered gut microbiota is reported in metabolic disorders. Here we provide evidence linking gut microbiota and metabolic diseases, focusing on the pathogenetic mechanisms underlying this association. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
43. Role of diffusion-weighted imaging, apparent diffusion coefficient and correlation with hepatobiliary phase findings in the differentiation of hepatocellular carcinoma from dysplastic nodules in cirrhotic liver.
- Author
-
Inchingolo, Riccardo, De Gaetano, Anna, Curione, Davide, Ciresa, Marzia, Miele, Luca, Pompili, Maurizio, Vecchio, Fabio, Giuliante, Felice, and Bonomo, Lorenzo
- Subjects
- *
DIFFUSION magnetic resonance imaging , *LIVER cancer , *DYSPLASIA , *CIRRHOSIS of the liver , *LIVER diseases - Abstract
Objectives: To investigate the utility of diffusion-weighted imaging (DWI), apparent diffusion coefficient (ADC) and the correlation with hepatobiliary phase (delayed phase imaging, DPI) findings in the differentiation of cirrhotic hepatocellular nodules. Methods: Forty-three patients with 53 pathology-proven nodules (29 hepatocellular carcinomas (HCCs), 13 high-grade (HGDNs) and 11 low-grade dysplastic nodules (LGDNs); mean size 2.17 cm, range 1-4 cm), who underwent liver MRI with DWI and DPI sequences, were retrospectively reviewed. Lesions were classified as hypointense, isointense, or hyperintense relative to the adjacent liver parenchyma. ADC of each nodule, of the surrounding parenchyma, and lesion-to-liver ratio were calculated. Results: Hyperintensity versus iso/hypointensity on DWI, hypointensity versus iso/hyperintensity on DPI, and the mean lesion-to-liver ratio showed a statistically significant difference both between HCCs versus DNs and between 'HCCs + HGDNs' versus LGDNs ( p < 0.05); sensitivity, specificity, and accuracy for the diagnosis of 'HCCs + HGDNs' were 96.8 %, 100 %, 97.4 % respectively when combining hyperintensity on DWI and hypointensity on DPI, and 90.9 %, 81.0 %, 83.6 % respectively when lesion-to-liver ratio was <0.95. Conclusions: Hyperintensity on DWI, especially in association with hypointensity on DPI, and low lesion-to-liver ratios should raise the suspicion of HCC, or at least of HGDN, thus helping the characterization of atypically enhancing lesions. Key points: • Usefulness of DWI and ADC is shown in differential diagnosis of cirrhotic nodules. • Correlation of DWI with DPI improves differential diagnosis of cirrhotic nodules. • Characterization of atypically enhancing lesions becomes more confident. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
44. A 360-degree overview of paediatric NAFLD: Recent insights
- Author
-
Nobili, Valerio, Svegliati-Baroni, Gianluca, Alisi, Anna, Miele, Luca, Valenti, Luca, and Vajro, Pietro
- Subjects
- *
FATTY degeneration , *PEDIATRICS , *FIBROSIS , *JUVENILE diseases , *FATTY liver , *OBESITY , *DIAGNOSIS - Abstract
Summary: Non-alcoholic fatty liver disease (NAFLD) is a multi-faceted disorder, which ranges from simple steatosis to non-alcoholic steatohepatitis (NASH) with/without fibrosis. The effects of specific risk factors, such as obesity and sedentary lifestyle, on predisposing genetic settings eventually lead to the development of NAFLD in children. The complex interplay between genes and environment in NAFLD pathogenesis is sustained by multiple mechanisms that involve liver crosstalk with other organs and tissues, especially gut and adipose tissue. Unfortunately, natural history of paediatric NAFLD is lacking, and the etiopathogenesis is still in the process of being defined. Potential early predictors and suitable non-invasive diagnostic tools can be discovered based on the pathogenetic mechanisms and histological patterns. This will also help design novel treatments and a comprehensive and successful management strategy for patients. In this review, we discuss the recent advances made in genetics, etiopathogenesis, diagnosis, and therapeutic management of NAFLD, focusing especially on the obesity-related steatotic liver condition. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
45. Gallstone Disease Is Associated with More Severe Liver Damage in Patients with Non-Alcoholic Fatty Liver Disease.
- Author
-
Fracanzani, Anna Ludovica, Valenti, Luca, Russello, Maurizio, Miele, Luca, Bertelli, Cristina, Bellia, Alessandro, Masetti, Chiara, Cefalo, Consuelo, Grieco, Antonio, Marchesini, Giulio, and Fargion, Silvia
- Subjects
- *
GALLSTONES , *LIVER diseases , *OBESITY , *INSULIN resistance , *DIABETES , *BIOPSY - Abstract
Background: Nonalcoholic fatty liver disease (NAFLD) and gallstone disease (GD) are both highly prevalent in the general population and associated with obesity and insulin resistance. We aimed to evaluate the prevalence of GD in a cross sectional study of NAFLD patients and to define whether the presence of GD is associated with diabetes and predicts more severe liver disease. Methodology/Principal Findings: We merged databases of four Liver Units, comprising 524 consecutive biopsy-proven NAFLD (373 males) observed between January 2003 and June 2010. GD was diagnosed in 108 (20%), and 313 cases (60%) were classified by liver biopsy as nonalcoholic steatohepatitis (NASH). The GD subgroup was characterized by a significantly higher prevalence of females, prediabetes/diabetes, abdominal obesity and metabolic syndrome, older age, higher BMI, fasting glucose, HOMA-IR and lower ALT. The prevalence of GD progressively increased with advancing fibrosis and with the severity of necroinflammatory activity (p for trend = 0.0001 and = 0.01, respectively), without differences in the severity of steatosis. At multivariate analysis GD was associated with female gender (OR 1.37, 95% CI 1.04-1.8), age (OR 1.027, 95% CI1.003-1.05), fasting glucose (OR 1.21, 95% CI 1.10-1.33) and NASH (OR 1.40,95% CI 1.06-1.89), whereas ALT levels were associated with a lower GD risk (OR 0.98, 95% CI 0.97-0.99). When subjects with cirrhosis were excluded from analysis, the association between GD and fasting glucose, female gender, and NASH was maintained. Conclusion: Patients with NAFLD have a high prevalence of GD, which characterizes subjects with altered glucose regulation and more advanced liver disease. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
46. Silybin combined with phosphatidylcholine and vitamin E in patients with nonalcoholic fatty liver disease: A randomized controlled trial
- Author
-
Loguercio, Carmela, Andreone, Pietro, Brisc, Ciprian, Brisc, Michaela Cristina, Bugianesi, Elisabetta, Chiaramonte, Maria, Cursaro, Carmela, Danila, Mirela, de Sio, Ilario, Floreani, Annarosa, Freni, Maria Antonietta, Grieco, Antonio, Groppo, Marzia, Lazzari, Roberta, Lobello, Salvatore, Lorefice, Elisabetta, Margotti, Marzia, Miele, Luca, Milani, Stefano, and Okolicsanyi, Lajos
- Subjects
- *
FATTY liver , *SILIBININ , *LECITHIN , *VITAMIN E , *CLINICAL trials , *PLACEBOS , *CYTOKINES , *RANDOMIZED controlled trials - Abstract
Abstract: The only currently recommended treatment for nonalcoholic fatty liver disease (NAFLD) is lifestyle modification. Preliminary studies of silybin showed beneficial effects on liver function. Realsil (RA) comprises the silybin phytosome complex (silybin plus phosphatidylcholine) coformulated with vitamin E. We report on a multicenter, phase III, double-blind clinical trial to assess RA in patients with histologically documented NAFLD. Patients were randomized 1:1 to RA or placebo (P) orally twice daily for 12months. Prespecified primary outcomes were improvement over time in clinical condition, normalization of liver enzyme plasma levels, and improvement of ultrasonographic liver steatosis, homeostatic model assessment (HOMA), and quality of life. Secondary outcomes were improvement in liver histologic score and/or decrease in NAFLD score without worsening of fibrosis and plasma changes in cytokines, ferritin, and liver fibrosis markers. We treated 179 patients with NAFLD; 36 were also HCV positive. Forty-one patients were prematurely withdrawn and 138 patients analyzed per protocol (69 per group). Baseline patient characteristics were generally well balanced between groups, except for steatosis, portal infiltration, and fibrosis. Adverse events (AEs) were generally transient and included diarrhea, dysgeusia, and pruritus; no serious AEs were recorded. Patients receiving RA but not P showed significant improvements in liver enzyme plasma levels, HOMA, and liver histology. Body mass index normalized in 15% of RA patients (2.1% with P). HCV-positive patients in the RA but not the P group showed improvements in fibrogenesis markers. This is the first study to systematically assess silybin in NAFLD patients. Treatment with RA but not P for 12months was associated with improvement in liver enzymes, insulin resistance, and liver histology, without increases in body weight. These findings warrant further investigation. [Copyright &y& Elsevier]
- Published
- 2012
- Full Text
- View/download PDF
47. Risk of nonalcoholic steatohepatitis and fibrosis in patients with nonalcoholic fatty liver disease and low visceral adiposity
- Author
-
Fracanzani, Anna Ludovica, Valenti, Luca, Bugianesi, Elisabetta, Vanni, Ester, Grieco, Antonio, Miele, Luca, Consonni, Dario, Fatta, Erika, Lombardi, Rosa, Marchesini, Giulio, and Fargion, Silvia
- Subjects
- *
FATTY liver , *LIVER diseases , *OBESITY , *METABOLIC syndrome , *BODY mass index , *ALANINE aminotransferase , *GLUCOSE tolerance tests , *DISEASE risk factors - Abstract
Background & Aims: Increased visceral adiposity is considered the hallmark of the metabolic syndrome, whose hepatic manifestation is nonalcoholic fatty liver disease (NAFLD), although a subset of patients does not have visceral obesity. Our study aimed to compare metabolic alterations and liver damage in patients with NAFLD with and without visceral obesity. Methods: Four hundred and thirty one consecutive patients with liver biopsy-confirmed NAFLD were divided in three groups according to waist circumference, the simplest surrogate marker of visceral obesity. One hundred and thirty three patients (31%) had a waist circumference⩽94 (males) and⩽80cm (females) (group A), 157 (36%) between 94 and 102, and 80 and 88 (B), and the remaining 141 (33%) had values higher than 102 and 88cm (C). Results: Significant trends for older age, higher prevalence of female gender, lower HDL, higher triglycerides, altered glucose metabolism, hypertension, and metabolic syndrome were observed with increasing visceral adiposity. In contrast, non-alcoholic steatohepatitis (NASH) detected in 55% and 72% of patients with normal and increased waist circumference, respectively, and the presence of fibrosis⩾2 were not associated with visceral adiposity. Alanine aminotransferase (ALT), ferritin, HOMA-IR>4, and severe steatosis were independently associated with NASH, whereas ferritin and impaired glucose tolerance were associated with fibrosis⩾2. Conclusions: Patients with normal waist circumference, despite milder metabolic alterations, may have NASH and are at risk of developing fibrosis, suggesting that once NAFLD is present, visceral obesity is not a major determinant of liver damage severity. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
48. Intrafamilial transmission of hepatitis C virus in Italy: a systematic review.
- Author
-
de Waure, Chiara, Cefalo, Consuelo, Chiaradia, Giacomina, Sferrazza, Antonella, Miele, Luca, Gasbarrini, Giovanni, Ricciardi, Walter, Grieco, Antonio, and La Torre, Giuseppe
- Subjects
- *
CHI-squared test , *INFECTIOUS disease transmission , *COMPUTER software , *CONFIDENCE intervals , *FAMILIES , *HEPATITIS C , *MEDICAL information storage & retrieval systems , *MEDLINE , *ONLINE information services , *DATA analysis , *DISEASE prevalence , *DISEASE complications , *EPIDEMIOLOGY - Abstract
Background Hepatitis C virus (HCV) transmission is mainly due to parenteral exposure; however, in absence of such risk factor, there are reports of intrafamilial spread of HCV and observational studies suggest an increased risk for households of infected subjects. The aim of our study was to systematically review and meta-analyse studies about HCV prevalence among households of HCV patients in Italy. Methods PubMed and Embase were searched to identify Italian studies about HCV intrafamilial transmission. Keywords used were: 'HCV', 'Hepatitis C', 'intrafamilial', 'family' and 'Italy'. Selected studies were reviewed to assess the quality and meta-analysed using StatsDirect software. Results 25 studies were selected. The pooled overall prevalence was 9% (95% CI 7.1% to 11.1%). The highest pooled prevalence was found among sexual partners of index cases: 14.7% (95% CI 10.7% to 19.2%) globally and 9.9% (95% CI 3.6% to 18.8%) and 17.6% (95% CI 12.1% to 24%) in northern and central-southern regions, respectively. The meta-analysis of high-quality studies yielded the lowest HCV prevalence. Conclusion To be a HCV patient household is a risk factor for HCV and counselling for these households should be provided. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
49. A Comparative Study of Serum Angiogenic Biomarkers in Cirrhosis and Hepatocellular Carcinoma.
- Author
-
Pocino, Krizia, Napodano, Cecilia, Marino, Mariapaola, Di Santo, Riccardo, Miele, Luca, De Matthaeis, Nicoletta, Gulli, Francesca, Saporito, Raffaele, Rapaccini, Gian Ludovico, Ciasca, Gabriele, and Basile, Umberto
- Subjects
- *
BIOMARKERS , *DISEASE progression , *CIRRHOSIS of the liver , *COMPARATIVE studies , *ENZYME-linked immunosorbent assay , *HEPATOCELLULAR carcinoma - Abstract
Simple Summary: The progression of liver disease is accompanied by pathological angiogenesis, a prerequisite for the development of HCC. In this paper, we analyzed the clinical significance of serum angiogenic markers VEGF, Ang-1, Ang-2, angiopoietin receptor Tie1/2, HGF, and PECAM-1 in 62 patients with liver disease, out of which 33 were diagnosed with HCC and 29 with liver cirrhosis without signs of neoplasia. Biomarkers levels were investigated as a function of "Model for End-Stage Liver Disease" (MELD) score and Fibrosis Index (FI). HCC patients showed higher HGF levels than ones with cirrhosis, while high Ang-1 levels appeared to have a protective role in HCC as well as prognostic significance; we also found a strong correlation between HGF levels, Ang-2, and VEGF levels, further supporting their role in tumor angiogenesis. Due to the complexity of angiogenesis and the small size of the study group, further investigations are widely desired especially in the era of immunotherapy and HCC-targeted anti-angiogenic drugs. Background: Hepatocellular carcinoma (HCC) is a global health problem associated with chronic liver disease. Its pathogenesis varies according to the underlying etiological factors, although in most cases it develops from liver cirrhosis. The disease progression is accompanied by pathological angiogenesis, which is a prerequisite that favors the development of HCC. Aims: This study aims at contributing to our understanding of the role of angiogenic factors in the progression of liver disease. For this purpose, we evaluate the clinical significance of serum angiogenic markers (VEGF, Ang-1, Ang-2, the angiopoietin receptor Tie1/2, HGF, and PECAM-1) first in cirrhotic and HCC patients separately, and then comparing cirrhotic patients with and without HCC. Materials and Methods: We enrolled 62 patients, out of whom 33 were diagnosed with HCC and 29 with liver cirrhosis without signs of neoplasia. Patients underwent venous blood sampling before and after receiving treatments for the diagnosed disease. Serum markers were evaluated using ELISA assays for Tie1 and the Bio-Plex Multiplex system for the remaining ones. Biomarker levels were investigated as a function of clinical scores for disease staging (MELD and Fibrosis Index, FI). Results: In cirrhotic patients, Ang-1 and Ang-2 correlate with MELD (ρAng-1 = −0.73, p = 2E−5) and FI (ρAng-1 = −0.52, p = 7E−3, ρAng-2 = 0.53, p = 3E−3). A reduction of Ang-2 levels (p = 0.047) and of the Ang-2/Ang-1 ratio (p = 0.031) is observed in cirrhotic patients diagnosed with viral hepatitis after antiviral treatments. In HCC patients, Ang-1 negatively correlates with FI (ρ = −0.63, p = 1E−4), and PECAM-1 positively correlates with MELD (ρ = 0.44, p = 0.01). A significant Ang-1 reduction was observed in deceased patients during the study compared to ones who survived (p = 0.01). In HCC patients, VEGF levels were increased after tumor treatment (p = 0.037). Notably, HGF levels in cirrhotic patients with HCC are significantly raised (p = 0.017) compared to that in those without HCC. Conclusions: Our results suggest that serum angiogenic markers, with emphasis on Ang-1/2, can contribute to the development of quantitative tools for liver disease staging and therapy monitoring. The comparison between cirrhotic patients with and without HCC suggests that HGF levels are potentially useful for monitoring the insurgence of HCC after a cirrhosis diagnosis. High Ang-1 levels in HCC patients appear to have a protective role as well as prognostic significance. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
50. Upper Limits of Downstaging for Hepatocellular Carcinoma in Liver Transplantation.
- Author
-
Biolato, Marco, Galasso, Tiziano, Marrone, Giuseppe, Miele, Luca, and Grieco, Antonio
- Subjects
- *
ALPHA fetoproteins , *PATIENT selection , *RADIOEMBOLIZATION , *CANCER chemotherapy , *METASTASIS , *EARLY detection of cancer , *CHEMOEMBOLIZATION , *CANCER patients , *ELIGIBILITY (Social aspects) , *LIVER transplantation , *TUMOR markers , *HEPATOCELLULAR carcinoma , *TRANSPLANTATION of organs, tissues, etc. - Abstract
Simple Summary: Currently, most transplant centres worldwide accept patients with hepatocellular carcinoma who underwent successful downstaging. Concurrently, the effectiveness of radiological and systemic therapies used for the downstaging of hepatocellular carcinoma are increasing. It is now more frequently observed that candidates for liver transplantation have an excellent response to downstaging, even if the baseline stage was well beyond the transplantable tumour. Downstaged patients have a higher risk of dropout from the waiting list and post-transplant recurrence if not transplanted in a short time. Since an increasing number of downstaged patients affects the waitlist dynamics, the definition of upper limits of downstaging is becoming a crucial issue. In this narrative review, we summarise current evidence on the downstaging of hepatocellular carcinoma for liver transplantation, including downstaging of patients with macrovascular invasion or extrahepatic metastasis at presentation and employment of the new systemic treatments for hepatocellular carcinoma. In Europe and the United States, approximately 1100 and 1800 liver transplantations, respectively, are performed every year for hepatocellular carcinoma (HCC), compared with an annual incidence of 65,000 and 39,000 new cases, respectively. Because of organ shortages, proper patient selection is crucial, especially for those exceeding the Milan criteria. Downstaging is the reduction of the HCC burden to meet the eligibility criteria for liver transplantation. Many techniques can be used in downstaging, including ablation, chemoembolisation, radioembolisation and systemic treatments, with a reported success rate of 60–70%. In recent years, an increasing number of patient responders to downstaging procedures has been included in the waitlist, generally with a comparable five-year post-transplant survival but with a higher probability of dropout than HCC patients within the Milan criteria. While the Milan criteria are generally accepted as the endpoint of downstaging, the upper limits of tumour burden for downstaging HCC for liver transplantation are controversial. Very challenging situations involve HCC patients with large nodules, macrovascular invasion or even extrahepatic metastasis at baseline who respond to increasingly more effective downstaging procedures and who aspire to be placed on the waitlist for transplantation. This narrative review analyses the most important evidence available on cohorts subjected to "extended" downstaging, including HCC patients over the up-to-seven criteria and over the University of California San Francisco downstaging criteria. We also address surrogate markers of biological aggressiveness, such as alpha-fetoprotein and the response stability to locoregional treatments, which are very useful in selecting responders to downstaging procedures for waitlisting inclusion. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.